Genenta Science (GNTA) Competitors $4.07 +0.15 (+3.70%) As of 04/25/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. ATAI, PVLA, AURA, CYRX, GLUE, PHAT, RNAC, TSVT, MNPR, and SEPNShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), Monte Rosa Therapeutics (GLUE), Phathom Pharmaceuticals (PHAT), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Monopar Therapeutics (MNPR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Phathom Pharmaceuticals Cartesian Therapeutics 2seventy bio Monopar Therapeutics Septerna Atai Life Sciences (NASDAQ:ATAI) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Which has more volatility & risk, ATAI or GNTA? Atai Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Which has preferable earnings & valuation, ATAI or GNTA? Genenta Science has lower revenue, but higher earnings than Atai Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtai Life Sciences$308K947.00-$40.22M-$0.93-1.57Genenta ScienceN/AN/A-$12.60MN/AN/A Is ATAI or GNTA more profitable? Genenta Science's return on equity of 0.00% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Atai Life SciencesN/A -65.75% -52.71% Genenta Science N/A N/A N/A Does the MarketBeat Community favor ATAI or GNTA? Atai Life Sciences received 327 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 66.53% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAtai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Genenta ScienceOutperform Votes787.50% Underperform Votes112.50% Does the media favor ATAI or GNTA? In the previous week, Genenta Science had 1 more articles in the media than Atai Life Sciences. MarketBeat recorded 3 mentions for Genenta Science and 2 mentions for Atai Life Sciences. Genenta Science's average media sentiment score of 0.85 beat Atai Life Sciences' score of 0.53 indicating that Genenta Science is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in ATAI or GNTA? 28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts prefer ATAI or GNTA? Atai Life Sciences presently has a consensus target price of $10.50, indicating a potential upside of 619.18%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 518.81%. Given Atai Life Sciences' higher possible upside, analysts clearly believe Atai Life Sciences is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAtai Life Sciences beats Genenta Science on 7 of the 13 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.89M$2.92B$5.44B$7.80BDividend YieldN/A1.91%5.43%4.30%P/E RatioN/A29.2222.1418.40Price / SalesN/A481.28389.70101.29Price / CashN/A168.6838.2034.62Price / Book3.343.036.664.18Net Income-$12.60M-$72.17M$3.21B$247.71M7 Day Performance4.12%8.86%6.16%6.56%1 Month Performance-2.16%-3.99%-2.86%-2.25%1 Year Performance55.98%-21.17%16.43%4.67% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science1.9891 of 5 stars$4.04+3.1%$25.00+518.8%+38.6%$73.89MN/A0.007Positive NewsATAIAtai Life Sciences2.6058 of 5 stars$1.42-3.4%$10.50+639.4%-20.7%$283.69M$308,000.00-1.7580Gap DownPVLAPalvella Therapeutics3.5279 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AHigh Trading VolumeAURAAura Biosciences2.3206 of 5 stars$5.57+3.9%$22.75+308.4%-24.0%$279.75MN/A-3.2250Positive NewsCYRXCryoport2.5654 of 5 stars$5.52-0.5%$11.67+111.4%-64.1%$275.50M$228.39M-1.631,020GLUEMonte Rosa Therapeutics3.018 of 5 stars$4.46-2.0%$15.50+247.5%-7.2%$274.34M$75.62M-2.4490Positive NewsPHATPhathom Pharmaceuticals3.64 of 5 stars$3.90-3.2%$21.83+459.8%-54.8%$271.58M$55.25M-0.69110Upcoming EarningsRNACCartesian Therapeutics1.7923 of 5 stars$10.34-1.5%$42.14+307.6%-43.4%$267.88M$38.91M-0.2064Positive NewsTSVT2seventy bio2.1516 of 5 stars$4.99+0.2%$5.60+12.2%+16.1%$261.17M$37.86M-2.68440Upcoming EarningsAnalyst ForecastNews CoverageMNPRMonopar Therapeutics2.5185 of 5 stars$42.71+7.9%$55.33+29.6%+1,261.3%$261.09MN/A-21.6810Positive NewsGap DownSEPNSepterna2.2809 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ALockup ExpirationPositive News Related Companies and Tools Related Companies Atai Life Sciences Competitors Palvella Therapeutics Competitors Aura Biosciences Competitors Cryoport Competitors Monte Rosa Therapeutics Competitors Phathom Pharmaceuticals Competitors Cartesian Therapeutics Competitors 2seventy bio Competitors Monopar Therapeutics Competitors Septerna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNTA Stock Free GNTA Stock Alerts